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Abstract
The emergence of highly pathogenic human coronaviruses (hCoVs) in the last two decades has illuminated their potential 
to cause high morbidity and mortality in human populations and disrupt global economies. Global pandemic concerns stem 
from their high mortality rates, capacity for human-to-human spread by respiratory transmission, and complete lack of 
approved therapeutic countermeasures. Limiting disease may require the development of virus-directed and host-directed 
therapeutic strategies due to the acute etiology of hCoV infections. Therefore, understanding how hCoV–host interactions 
cause pathogenic outcomes relies upon mammalian models that closely recapitulate the pathogenesis of hCoVs in humans. 
Pragmatism has largely been the driving force underpinning mice as highly effective mammalian models for elucidating 
hCoV–host interactions that govern pathogenesis. Notably, tractable mouse genetics combined with hCoV reverse genetic 
systems has afforded the concomitant manipulation of virus and host genetics to evaluate virus–host interaction networks 
in disease. In addition to assessing etiologies of known hCoVs, mouse models have clinically predictive value as tools to 
appraise potential disease phenotypes associated with pre-emergent CoVs. Knowledge of CoV pathogenic potential before it 
crosses the species barrier into the human population provides a highly desirable preclinical platform for addressing global 
pathogen preparedness, an overarching directive of the World Health Organization. Although we recognize that results 
obtained in robust mouse models require evaluation in non-human primates, we focus this review on the current state of 
hCoV mouse models, their use as tractable complex genetic organisms for untangling complex hCoV–host interactions, and 
as pathogenesis models for preclinical evaluation of novel therapeutic interventions.
Introduction
The etiologies of coronaviruses (CoVs) comprise an exten-
sive host range that includes reptiles, birds, pigs, dogs, cats, 
cattle, rodents, bats, camels, and humans. The extensive non-
human host range may serve as reservoirs for pre-emergent 
coronaviruses poised for zoonotic transmission into human 
and animal populations (Forni et  al. 2017; Zhou et  al. 
2018). There are six known human coronaviruses (OC43, 
229E, NL-63, HKU1, SARS-CoV, and MERS-CoV), four 
of which (NL-63, HKU1, SARS-CoV, and MERS-CoV) 
were identified in the last 15 years. Considering that bats 
may be the pinnacle reservoir for the origin of most hCoVs 
(SARS-CoV, MERS-CoV, 229E, and NL63), evidence for 
SARS-CoV and MERS-CoV indicates that intermediate 
zoonotic hosts (civet cat and camel, respectively) may be as 
important for the evolution of a pathogenic CoV to emerge 
into the human population (Forni et al. 2017). The emer-
gence of novel pathogenic CoVs into the human population 
can result in highly lethal respiratory hCoVs with global 
pandemic potential through human-to-human spread, which 
is underscored by the global spread of SARS-CoV (~ 10% 
mortality) in 2002–2003 and the ongoing re-introduction of 
MERS-CoV (~ 35% mortality) into humans on the Arabian 
Peninsula. Human-to-human transmission of MERS-CoV 
was most apparent in the South Korean outbreak in 2015, 
established by a single individual returning from a visit 
to the Arabian Peninsula, and resulting in 186 individuals 
infected with an ~ 20% mortality rate (Lee 2015). The high 
mortality rate in South Korea also established a society-wide 
panic that led to a severe economic toll, anticipated to cut 
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0.1% from the GDP rate in 2015 (Lee 2015). Once an hCoV 
emerges in humans new tools and robust mouse models are 
needed to decipher pathogenic mechanisms. Ultimately, 
understanding the hCoV–host molecular interaction net-
works that regulate pathogenesis can guide the engineering 
of therapeutic countermeasures.
An ideal strategy for development of models that reca-
pitulate human respiratory CoVs clearly includes the devel-
opment of a genetically tractable mammalian model that 
effectively recapitulates human pathogenic phenotypes, and 
an efficient reverse genetics system for seamless manipu-
lation of the hCoV genome. Genetic control of both host 
and hCoV genomes facilitates the ability to draw cause-
and-effect relationships between virus/host genetics and 
pathogenic outcomes. Reverse systems genetic tools were 
developed to manipulate the large hCoV genomes (~ 30 kb) 
that encode 16 non-structural proteins; structural proteins 
including spike (S), envelope (E), membrane (M), and nucle-
ocapsid (N); and a number of accessory proteins that vary in 
sequence and function (Fig. 1) [reviewed in (Cockrell et al. 
2017)]. A number of in vitro experiments (biochemical and 
tissue culture based) demonstrated that hCoV proteins inter-
act with host cell proteins to ensure fidelity during virus rep-
lication or facilitate evasion of host cell immune responses. 
The most prominent hCoV–host cell interaction is between 
the major determinant of viral tropism, the spike protein, and 
a host cell-specific receptor. The spike protein forms a trimer 
on the surface of the virus with each monomer harboring a 
receptor binding domain (RBD) that interacts with its cog-
nate receptor on the host cell (ACE2 for SARS-CoV and 
DPP4 for MERS-CoV) (Fig. 2). The spike protein, especially 
the RBD, is a major target for development of antibody and 
vaccine therapeutics. Other highly conserved structural and 
non-structural proteins, chiefly enzymatic proteins, may 
serve as targets for broadly effective anti-hCoV therapeutic 
targets. The accessory proteins are not conserved between 
hCoVs, and numerous studies revealed that these gene sets 
encode critical determinants of species-specific pathogenesis 
by modulating host immune responses (Fig. 1). In vitro stud-
ies have shown a number of accessory proteins to be impor-
tant for evasion of host innate immune responses through 
interactions with host proteins [reviewed in (de Wit et al. 
2016; Totura and Baric 2012)]. Although in vitro studies 
are imperative for understanding molecular and biochemical 
mechanisms, only in vivo studies can decipher how complex 
hCoV–host interactions relate to pathogenic phenotypes fol-
lowing a respiratory infection.
Discerning the fine balance between pathogenesis and 
protection, that is governed by the relationship between host 
innate and adaptive immune responses, requires the devel-
opment of mammalian models that effectively recapitulate 
the pathogenesis of respiratory hCoVs. The challenges 
associated with modeling pathogenesis of emergent and 
pre-emergent hCoVs are borne out of models developed for 
SARS-CoV and MERS-CoV over the last 15 years (Table 1; 
Fig. 2). Mice, ferrets, and non-human primates (NHPs) are 
traditionally used for the studies involving respiratory path-
ogens and are among the species initially investigated for 
SARS-CoV and MERS-CoV replication and pathogenesis in 
the lungs. Taking into account a number of practical consid-
erations when comparing models for both SARS-CoV and 
MERS-CoV, mouse models appear to be the most pragmatic 
(Table 1). Although we emphasize the practicality of hCoV 
mouse models for the purposes of this review and the abso-
lute critical need for robust primate models for downstream 
drug and vaccine testing, it is important to note that research 
(e.g., efficacy of therapeutic countermeasures) established 
in a robust mouse model should effectively translate to large 
animal models, such as NHPs, that more closely reflect 
human physiology.
In general, mouse models for both SARS-CoV and 
MERS-CoV are affordable, readily available, require 
Fig. 1  Emergent and pre-emergent coronavirus genome organiza-
tion. The Orf1a and Orf1b genes (green) encode 16 non-structural 
proteins (nsp1–nsp16) that are highly conserved throughout coronavi-
ruses. The structural genes (red) encode the structural proteins spike 
(S), envelope (E), membrane (M), and nucleocapsid (N), which are 
common to all coronaviruses. The accessory genes (dark shade) are 
unique to different coronaviruses with regard to number, genomic 
organization, sequence, and function
nominal training for handling, amenable to manipulation 
under BSL3 conditions, amenable to analysis with com-
mercially available molecular reagents, amenable to large 
numbers for purposes of experimental reproducibility, and 
are genetically tractable (Table 1). Despite these commonali-
ties, establishing a mouse model for MERS-CoV presented 
challenges not encountered with SARS-CoV (Table 1). Even 
now, 6 years after the first case of MERS-CoV, one of the 
biggest challenges remains a very limited understanding of 
the pathology of MERS-CoV in humans. Only two stud-
ies have described the pathology of MERS-CoV in two 
fatal human cases (Alsaad et al. 2017; Ng et al. 2016). The 
two fatal human MERS-CoV cases were similar to those 
observed in cases of SARS-CoV, wherein patients exhib-
ited severe acute respiratory distress with diffuse alveolar 
damage and formation of hyaline membranes, alveolar fibrin 
deposits, edema, hemorrhaging, cellular debris, alveolar and 
interstitial inflammation throughout lungs, and extensive 
pulmonary tissue necrosis (Alsaad et al. 2017; Ng et al. 
2016). Fatal cases of SARS-CoV and MERS-CoV were 
commonly associated with a gradual loss of respiratory 
function with available intervention restricted to mechanical 
respiratory support and oxygen supplementation [reviewed 
in (Arabi et al. 2017)]. Therefore, effective mouse models 
for SARS-CoV and MERS-CoV should minimally be able 
to recapitulate fatal respiratory disease having pathology 
similar to that observed in humans. As described below, a 
number of mouse models exhibiting fatal respiratory disease 
were developed for SARS-CoV and MERS-CoV; however, 
a single impediment was realized early in model develop-
ment for MERS-CoV that was not confronted for SARS-
CoV. The mouse orthologue of the human receptor for 
MERS-CoV, dipeptidyl peptidase 4 (DPP4), did not support 
interaction with the MERS-CoV spike glycoprotein RBD 
(Cockrell et al. 2014). Therefore, unlike SARS-CoV, com-
mercially available mice were not susceptible to MERS-CoV 
Fig. 2  Mouse model development should be tailored to the corona-
virus of interest. Mouse-adapted SARS-CoV column (blue). SARS-
CoV infects humans via an interaction of the spike protein [RCSB 
PDB ID: 5X58 (Yuan et al. 2017)] with its cognate receptor, ACE2 
[RCBS PDB ID: 1R42 (Towler et  al. 2004)]. In order to establish 
lethal mouse models, the spike protein, and other genomic determi-
nants, have been modified through adaptive evolution in mouse lungs 
(Day et al. 2009; Frieman et al. 2012; Roberts et al. 2007a). Thereby, 
any mouse subspecies that exhibits an unaltered mouse Ace2 can be 
infected with the mouse-adapted SARS-CoV. Wild-type MERS-CoV 
column (green). MERS-CoV infects humans via an interaction of 
the spike protein [RCSB PDB ID: 5X5F (Yuan et al. 2017)] with its 
cognate receptor, DPP4 [RCSB PDB ID: 2ONC (Feng et al. 2007)]. 
The MERS-CoV spike protein is not able to interact with the mouse 
orthologue of human DPP4 (Cockrell et  al. 2014; Coleman et  al. 
2014). Therefore, the mouse Dpp4 gene had to be genetically modi-
fied in order to allow for infection with MERS-CoV (Cockrell et al. 
2016; Li et al. 2017; Pascal et al. 2015). Pre-emergent CoVs column 
(grey). Pre-emergent CoVs can use either known human receptors for 
CoVs (ACE2 or DPP4) (Ge et al. 2013; Menachery et al. 2015; Wang 
et al. 2014; Yang et al. 2016, 2014), or novel, unknown receptors to 
infect their host. The genetically highly diverse panel of mouse strains 
from the Collaborative Cross has the potential to provide mouse 
models for studies of newly emerging CoVs due to the high genetic 
variability present in this resource. For all virus images: yellow rep-
resents the envelope protein; light/dark blue represents the membrane 
protein; and red represents the nucleocapsid protein
infection and replication (Coleman et al. 2014). Susceptibil-
ity and MERS-CoV pathogenesis was achieved using unique 
approaches to genetically engineer mice, as described in 
detail below. Establishing mouse models of fatal disease 
for SARS-CoV and MERS-CoV has afforded the necessary 
knowledge to institute a preclinical in vivo platform that can 
be used to evaluate pre-emergent hCoV respiratory patho-
gens with unknown disease outcomes (Fig. 2). The strategy 
is widely portable to other important human pathogens that 
replicate poorly or not at all in the mouse.
Mouse models for SARS‑CoV pathogenesis
The need for SARS-CoV mouse models was recognized 
shortly after the SARS-CoV outbreak that spread globally 
in 2002–2003. Three different strategies were employed for 
development of SARS-CoV mouse models: (i) different 
mouse species (or subspecies) were challenged with wild-
type human SARS-CoV isolates in order to find a model 
that allows for replication and reflects severe respiratory 
disease symptoms observed in infected human patients; (ii) 
mice were genetically engineered to modify the host recep-
tor, which facilitated productive SARS-CoV replication 
and pathogenesis; and (iii) adaptive evolution of wild-type 
SARS-CoV to a chosen mouse species was done to enhance 
pathogenesis, and associated clinical phenotypes in vivo.
Initial studies to develop a mouse model for SARS-CoV 
evaluated the susceptibility of various mouse subspecies 
to clinical isolates of SARS-CoV. In early 2004, the first 
study using the mouse as a model organism for SARS-CoV 
was reported (Subbarao et al. 2004). 4–6 weeks old female 
BALB/c mice were intra-nasally infected with a clinical iso-
late of SARS-CoV (Urbani) and efficient viral replication 
was observed from the upper and lower respiratory tract with 
peak titers on day 3 and clearance by day 7, whereas viral 
replication was not detected in other organs. However, mice 
continued to gain weight and did not show other signs of 
clinical disease. Passive transfer of immune sera to naïve 
mice was sufficient to prevent viral replication in the res-
piratory tract, indicating that wild-type SARS-CoV could 
elicit an effective humoral immune response. Nonethe-
less, in the absence of pathogenesis with no clinical signs 
of disease, it is difficult to properly evaluate the efficacy 
of therapeutic countermeasures. In a second study, Glass 
et al. used C57BL/6 mice which were known to exhibit a 
Th1-biased immune response in contrast to BALB/c mice 
Table 1  Practical considerations for establishing an effective HCoV animal model
a Yes—required virus adaptation
b Yes—after genetically engineering a mouse
c Affordability—more cost effective relative to ferret and NHP models
d Availability—developed models that can be readily acquired and studied by the broader scientific community
e Ease of handling—mice require least amount of specialized training compared to ferrets and NHPs
f Amenable to ABSL3 conditions—mice are most amenable to ABSL3 conditions due to space limitations, specialized handling requirements, 
and personnel limitations
g Maybe—dependent on species and techniques
h N/D—not determined
that were considered to be Th2-biased (Glass et al. 2004), 
which may account for differences in pathogenic outcomes. 
Like the BALB/c study, 5–6 weeks old C57BL/6 mice 
were infected with the clinical SARS-CoV Urbani isolate. 
Infected C57BL/6 mice exhibited slower weight gain than 
mock-infected mice and SARS-CoV was found not only in 
the upper and lower respiratory tract but also in the brain, 
which was not associated with clinical disease in humans. 
Developing a SARS-CoV model in C57BL/6 mice had the 
added benefit of expanding the applicability of the model 
to genetically modified knock-out (KO) mice that are pre-
dominantly generated on a C57BL/6 background, thereby 
facilitating the investigation of host genetics on SARS-CoV 
pathogenesis (Glass et al. 2004). Utilizing CD-1−/− and 
Rag−/− knock-out mice, Glass et al. demonstrated that NK 
cells, NK-T cells, or T and B lymphocytes are not required 
for clearance of SARS-CoV in the mouse (Glass et al. 2004). 
These initial studies to evaluate different murine subspecies 
as models for SARS-CoV resulted in replication in the res-
piratory tract with no indication of the clinical pathogenesis 
often observed in human cases experiencing severe respira-
tory distress.
Knock-out mice deficient in the innate immune response 
were the first to exhibit clinical alterations that included 
weight loss and progressively worsening pulmonary dis-
ease (Hogan et al. 2004). 129SvEv and Stat1−/− mice on 
a 129SvEv background infected with a SARS-CoV clini-
cal isolate (Toronto-2) showed that Stat1 was required for 
the resolution of SARS-CoV infection. Clinical signs of 
disease were only observed in KO mice, whereas efficient 
viral replication in the lower respiratory tract caused no 
clinical symptoms in 129SvEv wild-type mice. In contrast, 
Stat1−/− mice supported viral replication with peak titers on 
day 3 and persistence throughout day 22 (Hogan et al. 2004). 
Most features of pathology that were found in Stat1−/− mice 
were different from those found in humans. However, some 
pathological features common to humans, such as bronchi-
olar injury with focal respiratory epithelial cell necrosis, 
supported the idea that the mouse species could be a good 
model for SARS-CoV-associated clinical findings observed 
in the respiratory tract of infected human patients.
Increased fatality as consequence of acute respiratory 
distress syndrome (ARDS) from SARS-CoV infection 
was often associated with advanced age (> 60 years old) 
in humans (Booth et al. 2003; Donnelly et al. 2003; Tsui 
et al. 2003), which was exploited to improve mouse mod-
els of SARS-CoV pathogenesis. To replicate advanced 
age in humans, 12–14 months old BALB/c (Roberts et al. 
2005), C57BL/6, and 129S6 (Roberts et al. 2008) mice were 
intra-nasally infected with a clinical isolate of SARS-CoV 
(Urbani). BALB/c and C57BL/6 mice showed comparable 
levels and kinetics of viral replication while aged 129S6 
mice cleared SARS-CoV by day 5 (Roberts et al. 2008). 
The predominant clinical feature regarding mouse studies 
is weight loss, a consequence of appetite loss and dehydra-
tion. All three lines of aged mice showed transient signs of 
clinical disease including weight loss, ruffled fur, hunching, 
and dehydration that resolved by day 7. Moreover, all three 
strains exhibited histopathological findings such as perivas-
cular and peribronchiolar infiltrates, necrotic debris in bron-
chioles, and interstitial pneumonitis. Importantly, extensive 
alveolar damage in aged BALB/c mice persisted through 
day 9 post-infection (p.i.), findings that closely resembled 
pathology observed in humans. These are some of the first 
controlled studies to demonstrate that differences in host 
genetics can significantly influence SARS-CoV pathogen-
esis, a topic that is revisited below with regard to using a 
tractable population of genetically distinct mice referred 
to as the Collaborative Cross. Concurrent with these stud-
ies, Rockx et al. demonstrated that pathogenesis related to 
SARS-CoV clinical isolates was also dependent upon the 
genetics of the SARS-CoV strain evaluated in vivo (Rockx 
et al. 2007). Using reverse genetics Rockx et al. modified the 
spike protein from the SARS-CoV Urbani strain to encode 
the spike from middle (CUHK-W1) and early (GZ02) 
phase clinical isolates or a civet strain spike gene from HC/
SZ/61/03 (Rockx et al. 2007). An infectious clone harbor-
ing the clinical isolate GZ02 or civet HC/SZ/61/03 spikes 
exhibited severe weight loss and death, as well as pathology 
consistent with acute respiratory distress syndrome in aged, 
but not young mice (Rockx et al. 2007). Despite these early 
achievements with aged mice for SARS-CoV mouse model 
development, it is impractical to maintain large colonies of 
aged mice; and immune senescence in aged mice may com-
plicate studies involving pathogenesis and effective evalua-
tion of immune responses to therapeutic countermeasures. 
In addition to these limitations, full-length clinical isolates 
of SARS-CoV were not shown to be lethal in aged mice, 
a clinical outcome that impacted nearly 10% of all human 
cases.
Lethality was not achievable using clinical SARS-CoV 
isolates in various young wild-type or immune-incompetent 
mouse strains. With this in mind, attention turned to genetic 
modification of mice to acquire a lethal model for SARS-
CoV pathogenesis. In order to continue working with unal-
tered human clinical isolates of SARS-CoV, mouse strains 
constitutively expressing the human receptor for SARS-
CoV, human angiotensin converting enzyme 2 (hACE2), 
were generated. The logic followed that human clinical 
isolates of SARS-CoV are evolved to use the hACE2 recep-
tor more effectively than the innate mouse ACE2 (mACE2) 
receptor; therefore, may elicit pathology consistent with a 
lethal respiratory infection. Different constitutive promotors 
were used to express hACE2 in mice: cytokeratin promotor 
(McCray et al. 2007; Netland et al. 2008), chicken beta-actin 
promotor with a cytomegalovirus IE enhancer (Tseng et al. 
2007), and the mouse ACE2 promotor (Yang et al. 2007). 
Expression levels of human ACE2 correlated with disease 
severity in all transgenic mouse models. Human ACE2 over-
expression mice generated with the cytokeratin promoter 
and the mACE2 promoter were attempts to limit expression 
to respiratory cells and cells that exhibited innate mACE2 
receptor expression, respectively (McCray et  al. 2007; 
Netland et al. 2008; Yang et al. 2007). Even though these 
transgenic mice showed infection of airway epithelium, all 
of them exhibited high levels of hACE2 expression in the 
brains of transgenic mice which supported increased viral 
load in brain tissue (McCray et al. 2007; Netland et al. 2008; 
Tseng et al. 2007; Yang et al. 2007). The increased viral 
loads in the brains of infected animals ultimately led to mor-
tality caused by extensive dissemination and encephalitis in 
the brain (McCray et al. 2007; Netland et al. 2008; Tseng 
et al. 2007; Yang et al. 2007). Accordingly, despite the suc-
cessful generation of lethal hACE2 overexpression mouse 
models for SARS-CoV pathogenesis, neurological-related 
mortality confounded their value as models that could effec-
tively mimic lethal respiratory disease often observed in 
infected humans.
Adaptive experimental evolution has been a staple 
of virology for > 60 years (Kalter 1949), providing criti-
cal insights into pathogenic mechanisms while bestowing 
robust, lethal mouse models to interrogate the efficacy of 
vaccines and therapeutics (Bolles et al. 2011; Cockrell et al. 
2016; Rasmussen et al. 2014; Roberts et al. 2007a). Adap-
tive experimental evolution is performed by serial in vivo 
passages in the tissue of interest to adapt the virus to the 
host innate and adaptive immune responses. This is similar 
to the ongoing battle between a virus and the host immune 
responses occurring in nature, but on an expedited time-scale 
and in a tissue-specific manner. Tissue-specific adaptive evo-
lution places the virus under selective pressure for mutations 
that allow for more efficient replication. To adapt SARS-
CoV to cause severe acute respiratory disease in mouse 
lungs, 6-week-old female BALB/c mice were intra-nasally 
infected with the clinical Urbani isolate (Roberts et  al. 
2007a). This process was repeated (15 rounds) until signs 
of clinical disease were observed, predominantly weight 
loss that reached clinical endpoints for humane euthanasia 
(considered humane lethality) (Roberts et al. 2007a). The 
resulting mouse-adapted SARS-CoV was designated MA15. 
Rapid weight loss was accompanied by high viral titer in the 
lungs, viremia and dissemination to extrapulmonary sites, 
lymphopenia, neutrophilia, and histopathological changes in 
the lung commonly associated with pneumonitis. Accord-
ingly, mortality was a consequence of extensive viral repli-
cation which led to virus-associated destruction of pneumo-
cytes and epithelial cells. Only six coding mutations were 
sufficient to render the SARS-CoV Urbani human clinical 
isolate 100% lethal in 4 weeks old, 6–8 weeks old, and aged 
BALB/c mice (Roberts et al. 2007a). The MA15 SARS-CoV 
has since been used in a multitude of studies and proven to 
not only cause lethal disease in BALB/c mice but also in 
other mouse strains (Deng et al. 2014; Frieman et al. 2010; 
Gralinski et al. 2015, 2017; Totura et al. 2015; Zhao et al. 
2012). Additional passaging of MA15 resulted in the genera-
tion of other mouse-adapted SARS-CoV strains including 
MA20 (20 passages) (Frieman et al. 2012), while an inde-
pendent research group acquired a lethal SARS-CoV model 
by passaging the human Urbani isolate 25 rounds through 
the lungs of BALB/c mice, resulting in v2163 (Day et al. 
2009). In addition to acquiring lethal SARS-CoV models 
of disease, comparing various passages of mouse-adapted 
SARS-CoV provides the unique advantage of being able to 
identify which SARS-CoV proteins acquire specific muta-
tions that can elicit severe respiratory phenotypes. Identi-
fication of adaptive mutations acquired in specific SARS-
CoV proteins provided insight into virus–host interaction 
networks that may be used for the development of virus-
directed therapeutic countermeasures. Combining mouse-
adapted SARS-CoV strains with mouse models that support 
interrogation of the host genome for molecules that influ-
ence SARS-CoV pathogenesis can reveal import interaction 
nodes amenable to host-directed therapeutic intervention.
As mentioned above, a number of early SARS-CoV 
mouse model studies showed that disease progression and 
outcome are mouse strain dependent, indicating that host 
genetics have a considerable influence on SARS-CoV patho-
genesis. This is not surprising since human gene associa-
tion studies have indicated that differences in an individual’s 
genetics may govern susceptibility and clinical outcomes of 
respiratory viral pathogenesis (Everitt et al. 2012; Forton 
et al. 2009; Kenney et al. 2017; Mills et al. 2014; Pasanen 
et al. 2017; Patarcic et al. 2015; Zhou et al. 2012), includ-
ing retrospective studies of SARS-CoV-infected patients 
(Chan et al. 2007, 2006; Ching et al. 2010; Wang et al. 
2008; Zhu et al. 2011). However, human genetic associa-
tions do not indicate cause-and-effect, which require the 
capacity to model the impact of host genetics on respiratory 
viral pathogenesis, in this case SARS-CoV pathogenesis. 
A recently developed, innovative resource for genetic map-
ping, called the Collaborative Cross (CC), comprises a panel 
of recombinant inbred mouse strains containing tractable 
genetic diversity that approaches the genetic diversity in the 
human population (Churchill et al. 2004; Threadgill et al. 
2002). Using an octo-parental breeding scheme that includes 
classical laboratory stains (A/J, C57BL/6J, and 129/SvImJ), 
mouse models for human diseases (NOD/ShiLtJ for diabe-
tes; NZO/HlLtJ for obesity), and wild-derived mouse strains 
(CAST/EiJ, PWK/PhJ, and WSB/EiJ), the CC captures 90% 
of the genetic variation present in the three major mouse 
subspecies (Mus musculus musculus, Mus musculus domes-
ticus, Mus musculus castaneus) (Roberts et al. 2007b). Virus 
infection studies in CC mouse lines, including SARS-CoV, 
have led to mapping of high and low host response alleles 
as they relate to development of clinical signs of disease 
following viral pathogenesis (Bottomly et al. 2012; Brink-
meyer-Langford et al. 2017; Ferris et al. 2013; Gralinski 
et al. 2015, 2017; Green et al. 2017; Rasmussen et al. 2014). 
Rapid genetic mapping is most successful through compara-
tive analysis of CC strains that show extreme phenotypes 
such as high versus low weight loss, or high versus low lung 
titers. Extreme phenotypes in select CC strains may reflect 
clinical outcomes observed in human disease, as observed 
in testing mouse-adapted Ebola virus in different CC strains 
(Rasmussen et al. 2014). Applying the CC technology to 
SARS-CoV pathogenesis identified two CC strains (CC003/
Unc and CC053/Unc) with opposing susceptibility profiles 
(Gralinski et al. 2017). Genetic mapping revealed an adap-
tor protein (Ticam2) in the toll-like receptor pathway as a 
strong candidate driving severe respiratory disease pheno-
types (Gralinski et al. 2017). Based on these observations, 
the CC mouse platform can be used to identify novel mouse 
models that recapitulate human clinical outcomes resulting 
from pathogenic viruses.
The CC mouse strains are an extraordinarily powerful 
platform to establish novel mouse models for emergent and 
pre-emergent isolates of respiratory coronaviruses. Harness-
ing the power of CC host genetic mapping will support the 
identification of novel hCoV–host molecular interaction 
networks that can be subsequently validated in genetically 
engineered mice. Innovations in gene editing technologies 
such as CRISPR/Cas9, TALENs, and synthetic zinc fingers 
have augmented the efficiency of genetic engineering in 
mice, making genomic modifications (i.e., allele-specific 
mutations, allele swaps, knock-outs, knock-ins) feasible in 
multiple mouse species, on a large-scale (Doench 2018; Kim 
and Kim 2014). Coincidentally, advances in the CRISPR/
Cas9 technology overlapped with the outbreak of MERS-
CoV in 2012, which was fortuitous for the development of 
lethal MERS-CoV mouse models.
Mouse models for MERS‑CoV pathogenesis
Building on expertise from the SARS-CoV outbreak, 
coronavirus researchers immediately recognized the over-
whelming need for an effective MERS-CoV mouse model 
following the emergence of MERS-CoV in 2012. However, 
researchers were perplexed to find that mouse lines conven-
tionally susceptible to SARS-CoV infection/replication were 
completely resistant to infection with clinical MERS-CoV 
isolates (Coleman et al. 2014). Initial studies demonstrated 
that non-human primates were susceptible to clinical isolates 
of MERS-CoV (de Wit et al. 2013b; Falzarano et al. 2014; 
Johnson et al. 2016, 2015; Munster et al. 2013); therefore, 
the inability to infect mice with MERS-CoV was likely not 
due to restriction by the host immune responses. This was 
validated in immune-incompetent mouse lines that also 
lacked the capacity for infection/replication of MERS-CoV 
(Coleman et al. 2014). Concurrent with some of the initial 
MERS-CoV studies in mice, Raj et al. identified a novel 
receptor for MERS-CoV, human dipeptidyl peptidase 4 
(hDPP4) (Raj et al. 2013). Unlike SARS-CoV which could 
infect mice through interaction of the RBD in the spike pro-
tein with the mACE2 receptor, mouse DPP4 (mDPP4) did 
not support an interaction with the MERS-CoV spike protein 
(Cockrell et al. 2014). Crystal structures of the MERS-CoV 
spike-hDPP4 interface revealed a number of specific amino 
acids necessary for an interaction between the RBD in spike 
and two specific domains, referred to as blades IV and V on 
the β-propeller structure, of the hDPP4 structure (Lu et al. 
2013; Wang et al. 2013). Ectopic expression studies with the 
mouse DPP4 receptor revealed that altering a minimum of 
two amino acids on the mDPP4 (positions A288 and T330) 
conferred susceptibility of the human fibroblast cell line, 
293T, to MERS-CoV infection (Cockrell et al. 2014; Peck 
et al. 2015). Importantly, in mice T330 is an N-linked gly-
cosylation site that may sterically hinder MERS-CoV infec-
tion, and is not present in DPP4 orthologues from suscepti-
ble species including human, NHPs, bats, and camels (Peck 
et al. 2015). Apparently, ferret and hamster DPP4 may also 
have similar glycosylation’s, which may explain the inability 
of MERS-CoV to also infect/replicate in these conventional 
small animal models (de Wit et al. 2013a; Peck et al. 2017; 
Raj et al. 2014; van Doremalen et al. 2014). Species-spe-
cific challenges utilizing the DPP4 receptor not only limited 
development of mouse models, but stymied development of 
all small animal models required for evaluating therapeutic 
countermeasures.
Accordingly, the initial development of mouse models 
for MERS-CoV required employing a number of methods 
that focused on engineering mice to express/overexpress the 
human DPP4 receptor (Agrawal et al. 2015; Li et al. 2016; 
Zhao et al. 2015, 2014) (Fig. 3). The first mouse model, 
developed by Zhao et al., established transient expression 
of human DPP4 in the airway of BALB/c mice, C57BL/6 
mice, and several knock-out mice using an adenoviral vector 
to transduce an hDPP4 overexpression cassette (Ad-hDPP4) 
to the lungs of mice (Zhao et al. 2014). Transient hDPP4 
expression rendered mice susceptible to clinical isolates of 
MERS-CoV infection [1 × 105 plaque forming units (PFU) 
dose], supporting viral replication in the lungs and produc-
ing transient weight loss with mild pneumonia, particularly 
in older and immunodeficient mice (Zhao et al. 2014). No 
mortality or signs of advanced clinical respiratory disease 
were observed (Zhao et al. 2014). As a platform strategy 
that could be applied to novel emerging viruses, the Ad-
hDPP4 model provided a means to rapidly evaluate MERS-
CoV-directed therapeutic countermeasures with regard to 
interfering with replication in the lungs of infected mice. 
Nevertheless, the Ad-hDPP4 model was not an effective 
means of understanding how therapeutic countermeasures 
could prevent development of severe respiratory disease that 
resulted in ~ 35% mortality in infected human cases.
To develop more clinically relevant mouse models, a 
number of groups turned to more conventional hDPP4 
knock-in approaches, resulting in ubiquitous, constitutive 
overexpression of hDPP4 throughout the mouse (Fig. 3). 
In 2015, Agrawal et al. reported development of a robust 
MERS-CoV mouse model by placing expression of hDPP4 
under the CAG promoter (Agrawal et al. 2015). Infection 
with clinical isolates of MERS-CoV resulted in high viral 
loads in the lungs that produced severe respiratory disease 
and was fatal by day 6 post-infection (Agrawal et al. 2015). 
However, disease was confounded by high viral loads in 
extrapulmonary tissues including the brain, heart, spleen, 
kidney, and intestines (Agrawal et al. 2015). In an independ-
ent study, Zhao et al. demonstrated multi-organ damage in 
an hDPP4 overexpression mouse model employing the same 
promoter (Zhao et al. 2015). The MERS-CoV viral loads 
were nearly two logs higher in the brains of infected mice 
than in the lungs and corresponded to viral encephalitis 
observed in the brain by day 9, with mice exhibiting signs 
of paralysis (Zhao et al. 2015). Li et al. went a step further by 
generating hDPP4 overexpression models with the goal of 
restricting expression to epithelial cells (Li et al. 2016). Two 
different models were generated using either the cytokeratin 
18 (K18) or surfactant C protein (SPC) promoter to drive 
expression of hDPP4. Mouse lines derived from the SPC-
hDPP4 cassette did not exhibit mortality or signs of respira-
tory disease. In contrast, infection of K18-hDPP4 mice with 
1 × 105 PFU of a MERS-CoV clinical isolate (EMC_2012) 
produced weight loss, lung hemorrhaging and mortality by 
6–7 days p.i., and lung pathology consistent with severe 
respiratory disease (Li et al. 2016). Unfortunately, the K18 
promoter did not limit MERS-CoV infection to the lungs, 
instead high viral loads in the brains of infected mice caused 
neurological disease that was consistent with the observed 
mortality (Li et al. 2016).
In a novel genetic engineering approach, Pascal et al. 
employed Regeneron’s VelociGene technology to precisely 
replace the entire mDPP4 coding region (~ 79 kb) with the 
hDPP4 gene, which included ~ 82 kb of sequence encod-
ing both introns and exons (Pascal et al. 2015) (Fig. 3). 
Despite removal of nearly the entire mDPP4 gene, the 5′ 
and 3′ untranslated regions of mDPP4 were maintained; 
thereby, retaining the endogenous mDPP4 promoter and 
RNA termination regions conferred expression levels and 
tissue distribution for hDPP4 similar to that obtained for 
mDPP4. Infection with 2 × 105 PFU of a MERS-CoV clini-
cal isolate resulted in viral replication in the lungs with mild 
clinical disease and pathology indicative of inflammation, 
with no weight loss or mortality through day 4 p.i. (Pas-
cal et al. 2015). Subsequent studies with the VelociGene 
mice comprised a more detailed evaluation of the model, 
wherein mice infected with 2.5 × 104 PFU achieved dramatic 
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Fig. 3  Comparison of mouse models for MERS-CoV. a Wild-type 
mouse DPP4 (mDPP4) with 26 exons (NM_010074.3). b Wild-
type human DPP4 (hDPP4) with 26 exons (NM_001935.3). c DPP4 
sequence used in VelociGene hDPP4 knock-in mouse model (Pas-
cal et al. 2015). Mouse genomic sequence, from exon 2 through the 
stop codon in exon 26, was deleted and replaced with exon 2 through 
exon 26 and a portion of 3′ untranslated sequence of human genomic 
sequence. d DPP4 sequence used in hDPP4 knock-in model (Li 
et  al. 2017). Mouse genomic sequence from codon I264 in exon 10 
to codon V340 in exon 12 was replaced with the human equivalent. 
e DPP4 sequence used in 288–330+/+ mouse model (Cockrell et  al. 
2016). CRISPR/Cas9 technology used to make A288L substitution in 
exon 10 and T330R substitution in exon 11 of mouse DPP4. f DPP4 
construct used in hDPP4 overexpression mouse models. Constructs 
included cDNA from human DPP4 flanked by constitutive promoter, 
polyadenylation signals, and other regulatory elements (Agrawal et al. 
2015); or by 5′ and 3′ genomic regions of human cytokeratin 18 or 
human surfactant protein C (Li et al. 2016)
(Coleman et al. 2017). Lung pathology indicated that mice 
developed moderate signs of respiratory infection with lit-
tle indication of severe respiratory disease. These studies 
were also the first indication that  CD8+ T cells and mac-
rophages play a significant role in MERS-CoV pathogenesis 
(Coleman et al. 2017). Importantly, MERS-CoV infection/
replication was primarily in the lungs, with little involve-
ment of extrapulmonary tissues (Coleman et al. 2017; Pascal 
et al. 2015). The lack of brain lesions in this model was a 
significant advancement over transgenic models that relied 
on global/ubiquitous hDPP4 expression. Nonetheless, this 
model is not readily available to the scientific community 
by Regeneron, and if the model is obtained it comes with 
a number of commercial restrictions from Regeneron that 
limit its utility when considering development of thera-
peutic countermeasures (declaration by the authors of this 
manuscript).
Another limitation often overlooked with hDPP4 expres-
sion models is the innate functions of DPP4 that have 
evolved in a species-specific manner to maintain various 
physiological processes inherent to the host. Altered DPP4 
activity and/or expression is associated with many pathologi-
cal conditions that include psycho-neuroendocrine disorders, 
solid tumor cancers, hematological malignancies, infectious 
disease, and autoimmune/inflammatory diseases (Klemann 
et al. 2016). The enormous biological breadth of DPP4 is 
predominantly through its enzymatic activity wherein it 
cleaves off the amino terminal dipeptides of various biologi-
cal substrates having l-alanine or l-proline at the penulti-
mate position (Klemann et al. 2016). One of the more impor-
tant physiological processes of DPP4, also known as CD26, 
is the modification of numerous cytokine and chemokines 
involved in the maintenance of immunological homeostasis 
(Klemann et al. 2016; Ohnuma et al. 2008). As a cell sur-
face molecule on  CD4+ and  CD8+ T cells, DPP4 influences 
numerous immunological processes including T cell activa-
tion and proliferation, cytokine production, differentiation to 
immunoglobulin producing plasma cells, and transendothe-
lial migration (Ohnuma et al. 2008). Therefore, overexpress-
ing full-length hDPP4 or replacing mDPP4 with full-length 
hDPP4 in the knock-in mouse models may significantly alter 
the inherent biological and immunological processes that 
mDPP4 has evolved to execute in a species-specific manner, 
in the mouse. Ultimately, if hDPP4 expression results in a 
modified immune response in mice, these could artificially 
influence the pathogenic outcomes of MERS-CoV infections 
and immunological responses that are central to evaluating 
the efficacy of therapeutic countermeasures.
The goal of the most recent generation of mouse models 
was to genetically modify the mDPP4 receptor so that it 
would be amenable to interaction with the MERS-CoV spike 
RBD and subsequent infection, thereby avoiding the need 
to introduce the hDPP4 receptor. Achieving a MERS-CoV 
susceptible mDPP4 with minimal modifications would be 
central to limiting any functional alteration to mDPP4 that 
could interfere with its broad influence over multiple host 
physiological processes. In 2016, Cockrell et al. utilized the 
CRISPR/Cas9 technology to make two amino acid substitu-
tions in the mDPP4 gene (A288L and T330R) of C57BL/6J 
mice (Cockrell et al. 2016) (Fig. 3). As discussed above, 
in vitro overexpression of the modified mDPP4 was previ-
ously found to alter the susceptibility of cell lines to MERS-
CoV infection (Cockrell et al. 2014; Peck et al. 2015). Mice 
with the modified DPP4 (referred to as 288–330+/+ mice) 
encode both amino acid substitutions on both chromo-
somes. Characterization of this model demonstrated that 
innate mDPP4 expression profiles and physiological pro-
cesses influenced by DPP4 (glucose metabolism and T cell 
activation) were not altered by the two amino acid modi-
fications of mDPP4. The 288–330+/+ mice infected with 
various isolates of MERS-CoV (clinical isolates, a camel 
isolate, and molecular clones) supported high viral repli-
cation in the lungs, but failed to exhibit clinical signs of 
disease (Cockrell et al. 2016). Adaptive evolution through 
15 rounds of serial passage in 288–330+/− mice yielded a 
mouse-adapted MERS-CoV capable of achieving lethality, 
decreased respiratory function, and lung pathology indica-
tive of severe acute respiratory distress syndrome at viral 
doses of 5 × 106 PFU (Cockrell et al. 2016). MERS-CoV 
infected 288–330+/+ mice that exhibited severe respiratory 
disease were absent of any detectable virus in the brain. The 
development of severe respiratory disease and mortality 
could be prevented using a MERS-CoV spike-directed vac-
cine, and through prophylactic administration of an antibody 
therapeutic (Cockrell et al. 2016). Although the 288–330+/+ 
model is highly effective for studying MERS-CoV pathogen-
esis and evaluating therapeutic countermeasures, the high 
infectious dose (5 × 106 PFU) required to achieve severe 
respiratory disease and mortality left room for improve-
ment. An additional 20 rounds of passaging resulted in a 
mouse-adapted virus capable of achieving similar severe 
respiratory disease and mortality, but at substantially lower 
doses  (103–105 PFU) (Douglas et al. 2018). Overall, lim-
iting changes in the mDPP4 receptor to two amino acids, 
researchers were able to minimize disruption of the natural 
expression levels, distribution, and biological functions of 
mDPP4. The 288–330+/+ MERS-CoV mouse model con-
tinues to have a central role in studies investigating MERS-
CoV pathogenesis and therapeutic countermeasures (Men-
achery et al. 2017b, c).
The most recent mouse model consists of a genetically 
modified mDPP4 receptor through replacement of exons 
10–12 (including introns) of the mDPP4 locus with the 
hDPP4 equivalent, resulting in a minimal knock-in mouse 
model referred to as hDPP4-KI (Li et al. 2017) (Fig. 3). 
Modification of mDPP4 in the hDPP4-KI model is much 
smaller than the Regeneron full-length hDPP4 knock-in 
model, but larger than the two amino acid modifications 
to mDPP4 in the 288–330+/+ model, placing it somewhere 
between the two types of models. Regarding biological 
and immunological function, it is not clear if the modified 
mDPP4 in the hDPP4-KI model has altered expression, bio-
distribution, or functional profiles compared to wild-type 
mDPP4 receptor. Nevertheless, the hDPP4-KI mice were 
susceptible to infection with clinical isolates of MERS-CoV, 
resulting in high levels of viral replication in the lungs but 
no signs of respiratory disease. A mouse-adapted MERS-
CoV was achieved through 31 serial passages of MERS-
CoV, inducing severe respiratory disease accompanied 
by high mortality at infectious doses of  104–105 PFU (Li 
et al. 2017). Similar to the 288–330+/+ model, the hDPP4-
KI model exhibited little involvement of extrapulmonary 
tissues in MERS-CoV pathogenesis (Li et al. 2017). The 
mouse-adapted viruses acquired by Li et al. revealed unique 
mutations in specific viral proteins that may be critical for 
achieving and evading host immune responses. Comparison 
of these viruses to those obtained by Douglas et al. demon-
strated that changes at amino acid 222 in the MERS-CoV 
spike protein may be critical to achieve lethal infection at 
low infectious doses (Douglas et al. 2018; Li et al. 2017). 
Importantly, this mutation was not present in earlier pas-
sages by Cockrell et al. in the 288–330+/+ model, which 
required high infectious doses to achieve severe respiratory 
disease and lethality (Cockrell et al. 2016). Mouse-adapted 
viruses, such as those used by Cockrell et al., Douglas et al. 
and Li et al. can help provide insight into adaptive evolution 
and identify specific mutations or regions of the virus that 
are important for enhancing virus fidelity in the host and/or 
evading the host immune responses.
Adaptations in MERS-CoV most notably occur in the 
spike region, which is an important determinant of host tro-
pism. Adapted MERS-CoV strains with mutations in this 
region may not provide an accurate representation of the 
observed viral pathogenesis in humans. Currently, achieving 
lethal disease in mice with clinical isolates of MERS-CoV 
require expression of full-length hDPP4, as demonstrated 
for the Regeneron hDPP4 knock-in mice. However, altering 
DPP4 significantly through overexpression or replacement 
of mDPP4 can disrupt the immunological homeostasis of 
the animal, making it difficult to analyze disease etiology 
and immune responses to therapeutic countermeasures. A 
MERS-CoV mouse model would ideally involve infection 
with clinical MERS-CoV isolates in an unmodified mouse. 
One possibility is utilizing CC mice, as described above for 
SARS-CoV, which offer a wider range of genetic variation 
than the genetically engineered C57BL/6 mice used in cur-
rently established mouse models. However, unlike SARS-
CoV, the CC mice are not susceptible to MERS-CoV. Cross-
ing various CC lines with mice that have minimal alterations 
to mDPP4 (e.g., 288–330+/+ mice), or direct genetic engi-
neering of CC lines using CRISPR/Cas9 technologies, can 
produce mouse lines that maintain native mouse DPP4 
expression, distribution, and functional profiles, but can be 
screened for differential susceptibility to clinical isolates of 
MERS-CoV. The capacity to genetically engineer receptors 
to alter mouse susceptibility to hCoV infection, combined 
with adaptive hCoV evolution and genetically diverse CC 
mouse strains, establishes a platform that can be used to 
evaluate the pathogenesis of pre-emergent hCoVs with 
unknown etiologies.
Identifying pre‑emergent hCoVs with pathogenic 
potential
The mouse tools founded from studies of SARS-CoV and 
MERS-CoV pathogenesis will aid in understanding if spe-
cific pre-emergent CoVs have pathogenic potential in mam-
malian models of severe respiratory disease. Most hCoVs 
(SARS, MERS, 229E, and NL63) are considered to have 
their origin in bats [reviewed in (Forni et al. 2017; Men-
achery et al. 2017a)]. Metagenomics analysis of various 
bat species has identified a diverse repertoire of SARS-
like (SL-bCoVs) and MERS-like (ML-bCoVs) bat coro-
naviruses (Ge et al. 2012, 2013; He et al. 2014; Lau et al. 
2015, 2010, 2005; Wu et al. 2016; Yang et al. 2016). Those 
with pre-emergent potential include SL-CoVs WIV1 and 
WIV16, shown to utilize the ACE2 receptor (Ge et al. 2013; 
Menachery et al. 2015; Yang et al. 2016), and an ML-CoV 
HKU4, demonstrated to utilize the DPP4 receptor for infec-
tion (Wang et al. 2014; Yang et al. 2014). Notably, WIV1 
and WIV16 are the only pre-emergent CoVs directly iso-
lated from bat feces on Vero E6 cells and shown to replicate 
in various cell lines expressing the human, or NHP, ACE2 
receptor (Ge et al. 2013; Yang et al. 2016). In contrast to 
WIV1 and WIV16, isolated HKU4 was not demonstrated to 
infect cells, but rather lentiviral particles pseudotyped with 
HKU4 spike protein supported efficient binding and infec-
tion of cells expressing hDPP4 (Wang et al. 2014; Yang et al. 
2014). The structure of CoV spike proteins in the context of 
pseudotyped lentiviral particles may differ to that in CoV 
particles, and may account for the difficulty of HKU4 infect-
ing and replicating on cells expressing hDPP4.
The spike proteins of many pre-emergent bat CoVs 
(bCoVs) have amino acid differences that preclude effi-
cient interaction with known human host receptors, such 
as hACE2 or mACE2. Transmission to intermediate hosts 
(civets or camels) and humans may require additional adap-
tations in the spike protein [reviewed in (Graham and Baric 
2010; Menachery et  al. 2017a)]. Therefore, to evaluate 
pathogenesis of pre-emergent bCoVs in mouse models, the 
spike proteins were replaced by generating infectious molec-
ular clones with known spike proteins from clinical isolates 
of SARS or mouse-adapted SARS-CoV (Agnihothram et al. 
2014; Becker et al. 2008; Menachery et al. 2015, 2016). 
The first of these studies derived an infectious molecular 
clone SL-bCoV from sequences of four previously identi-
fied SL-bCoVs (HKU3-1, HKU3-2, HKU3-3, and RP3) 
(Becker et al. 2008). The chimeric virus was able to replicate 
in BALB/c mouse lungs, but did not elicit signs of respira-
tory disease commonly associated with SARS-CoV (Becker 
et al. 2008). Similarly, a chimeric WIV1 (WIV1-MA15) rep-
licated in BALB/c mouse lungs, but was attenuated with 
regard to causing respiratory disease (Menachery et  al. 
2016). Attenuation of WIV1-MA15 was partially overcome 
by infecting HFH4 mice that overexpress the hACE2 recep-
tor (Menachery et al. 2016), indicating that mouse adapta-
tion of the WIV1-MA15 to mACE2 could enhance disease 
in wild-type BALB/c mice. Indeed, Agnihothram et al. dem-
onstrated that mouse adaptation of an infectious molecular 
clone of an HKU5-SE chimeric resulted in dramatic res-
piratory disease in aged BALB/c mice (Agnihothram et al. 
2014). HKU5 is closely related to MERS-CoV, but since 
there was no mouse model available for MERS-CoV at the 
time, it was more practical to replace the HKU5 spike with 
the mouse-adapted SARS-CoV spike. These studies dem-
onstrated that adaptive mutations outside of the spike are 
necessary to elicit respiratory disease in different mamma-
lian species. However, this was not the case for the SHC014 
bCoV chimeric virus (SHC014-MA15), which caused sig-
nificant weight loss in BALB/c mice and replicated to titers 
comparable to SARS-CoV MA15 in the lungs (Menachery 
et al. 2015). Moreover, wild-type SHC014 spike protein sup-
ported infection/replication in the lungs of BALB/c mice, 
but did not result in disease. Applying the classical approach 
of adapting SHC014 to mice by serial passaging may be 
beneficial, but can be time-consuming. Screening SHC014, 
or other pre-emergent bCoVs, in CC mouse strains has the 
potential to rapidly lead to mouse models capturing differ-
ent, or even all, aspects of clinical disease in human patients.
Evaluating therapeutic countermeasures in hCoV 
mouse models
The ultimate goal for mouse model development is capturing 
disease etiologies that closely reflect what is observed during 
human CoV infection, so the efficacy of various therapeu-
tic countermeasures can be evaluated for effective resolu-
tion of pathogenic outcomes. A number of hCoV-directed 
drug, antibody, and vaccine therapeutics were evaluated for 
efficacy against SARS-CoV until 2012 when the focus of 
therapeutic development shifted to MERS-CoV [reviewed 
in (Dyall et al. 2017; Zumla et al. 2016)]. Currently, there 
are no FDA-approved therapeutics for the specific treat-
ment of SARS-CoV or MERS-CoV. Various combina-
tions/types of broad spectrum antivirals (e.g., ribavirin) 
combined with interferon therapies (interferon α or β), and/
or immune modulators (e.g., corticosteroids) were ineffec-
tive for SARS-CoV and MERS-CoV, and in some cases 
appeared to worsen disease [reviewed in (Dyall et al. 2017; 
Zumla et al. 2016)]. A recent clinical trial seeks to interfere 
with MERS-CoV replication using a combination therapy 
that includes FDA-approved protease inhibitors (Lopinavir/
ritonavir) (https ://clini caltr ials.gov/ct2/show/study /NCT02 
84584 3). Repurposing FDA-approved drugs has been the 
interest of numerous therapeutic studies, but little is known 
regarding the efficacy of drug therapeutics against SARS-
CoV or MERS-CoV outside of cell-based in vitro studies 
[reviewed in (Dyall et al. 2017)]. Mouse models confer 
distinct advantages for therapeutic examination including 
cost savings through small scale production for testing, and 
experimental reproducibility.
The recent development of a novel nucleotide prodrug, 
GS-5734, demonstrated efficacy against Ebola virus in 
NHPs (Warren et al. 2016), and has since moved into phase 
2 clinical trials for Ebola [https ://clini caltr ials.gov/ct2/show/
NCT02 81858 2?cond=PREVA IL+IV&rank=1; (Dornemann 
et al. 2017)]. A recent study demonstrated broad spectrum 
efficacy of GS-5734 against multiple hCoVs (SARS-CoV, 
MERS-CoV, and NL63) and pre-emergent bCoVs (HKU3, 
HKU5, SCH014, and WIV1) on primary human airway epi-
thelial cells (Sheahan et al. 2017). Importantly, GS-5734 
exhibited in  vivo efficacy against SARS-CoV-induced 
immunopathology if the drug was administered prophylac-
tically, or a therapeutic dose 24-h post-infection (Sheahan 
et al. 2017). Delaying treatment until 48-h post-infection 
did not ameliorate disease symptoms. Although the kinetics 
of SARS-CoV pathogenesis will differ between mouse and 
human, these results indicate that the molecular programs 
leading to respiratory immunopathology are established 
shortly after infection, thereby limiting effective therapeu-
tic treatment to a short window, post-infection. The study by 
Sheahan et al. also demonstrates the importance of having 
mouse models that recapitulate severe respiratory disease 
often seen in humans (Sheahan et al. 2017). An effective 
therapeutic should not only prevent viral replication, but 
more importantly should effectively restrict respiratory 
pathogenesis. Achieving both may require therapeutic inter-
vention with a combination of an hCoV antiviral and a host-
directed therapy that curtails immunopathology associated 
with acute respiratory distress syndrome. Only in the last 
3 years have MERS-CoV mouse models, described above, 
become available to assess therapeutics; therefore, future 
studies will include evaluating in vivo efficacy of GS-5734 
against MERS-CoV in the 288–330+/+ model described 
above.
As an ongoing threat to worldwide public health, a plethora 
of therapeutic research focused on development of MERS-
CoV-specific antibodies and vaccines, both of which have been 
extensively reviewed [reviewed in (Arabi et al. 2017; Dyall 
et al. 2017; Okba et al. 2017)]. Importantly, few studies have 
evaluated the therapeutic efficacy of MERS-CoV antibod-
ies and vaccines in mammalian challenge models that elicit 
severe respiratory disease, often resulting in death (Cockrell 
et al. 2016; Munster et al. 2017; Tai et al. 2016; van Doremalen 
et al. 2017; Wang et al. 2018). Rather, many preclinical studies 
exhibited efficacy in the mouse or NHP challenge models with 
protection defined as reduced viral loads in the lungs by plaque 
assay or RT-PCR. Preclinical results have expedited the pro-
cess of moving some antibody and vaccine therapeutics into 
early clinical trials [reviewed in (Arabi et al. 2017; Dyall et al. 
2017; Okba et al. 2017)]. Based on results obtained in stud-
ies with GS-5734, it will be critical to determine efficacy of 
antibody and vaccine therapeutics in lethal respiratory models 
of MERS-CoV infection.
Vaccine countermeasures are not only being considered as 
intervention strategies for staving off disease in humans, but 
have also exhibited efficacy in dromedary camels, the MERS-
CoV zoonotic host (Haagmans et al. 2016; Muthumani et al. 
2015). Targeting zoonotic hosts, such as dromedary camels 
or bat populations, may be an effective means of curtailing 
transmission into the human population. Thinking beyond 
vaccine countermeasures, we now have the ability to harness 
genome editing technologies that could allow us to intervene 
with the process of zoonotic transmission. C57BL/6J mice 
were made susceptible to MERS-CoV by using CRISPR/Cas9 
technologies to modify two amino acids at positions 288 and 
330 on mouse DPP4, to the orthologous amino acids encoded 
by human DPP4 (Cockrell et al. 2016). Genetic modification 
of the human DPP4 orthologues in camel and bat to look like 
mouse DPP4 at these positions may result in camels and bats 
that are now resistant to MERS-CoV infection. Although intro-
duction of MERS-CoV-resistant bats into the environment 
may take a long time, camels are considered farm animals 
in many parts of Northern Africa and the Middle East with 
controlled breeding practices; therefore, it may be feasible to 
establish resistant herds that are unable to transmit MERS-
CoV to humans. Genome editing of farm animals is clearly 
achievable as recently demonstrated in pigs modified with 
CRISPR/Cas9 for genome-wide inactivation of porcine endog-
enous retroviruses (PERVs), thereby eliminating the potential 
of cross-species transmission of PERVs during xenotransplan-
tation of pig organs into humans, with the intention of easing 
the shortage of available human organs (Niu et al. 2017; Yang 
et al. 2015).
Conclusions
The combined power of genetic engineering of mice, reverse 
genetic systems for CoVs, mouse-adaptation, and geneti-
cally diverse mouse populations afford the tools to develop 
models that reproducibly recapitulate severe respiratory 
disease that can be caused by hCoVs in humans. Establish-
ing mouse models for SARS-CoV and MERS-CoV have 
largely depended on one or more of these tools. Regardless 
of how effective models for SARS-CoV and MERS-CoV 
are for studying pathogenesis and therapeutic interventions, 
there are drawbacks related to mouse-adapted and trans-
genic mouse models that alter susceptibility and pathogen-
esis to hCoVs. Acquired mutations associated with severe 
respiratory disease in mouse-adapted hCoVs may have no 
bearing on human pathogenesis or have altered pathogenic 
outcomes in humans. Genetically engineering a specific host 
species to enhance susceptibility restricts applications of the 
mouse model, requiring cross-breeding to introduce novel 
host mutations from knock-out mouse lines and CC mouse 
strains. This process is labor intensive and requires an exten-
sive timeline. Alternatively, one could introduce mutations 
directly into genetically diverse lines; however, this is not 
cost effective. Additionally, it is difficult to replicate and 
study co-morbidities in mice that are associated with lethal 
respiratory disease seen in humans. Pre-existing conditions 
such as advanced age, diabetes, chronic lung diseases, heart 
disease, and kidney disease have been reported in many 
of the severe/lethal MERS-CoV human cases [reviewed 
in (Arabi et al. 2017)]. One way to address many of these 
concerns could be to screen genetically diverse populations 
of mice (e.g., Collaborative Cross) with clinical isolates or 
infectious molecular clones of wild-type strains from emer-
gent, or pre-emergent, hCoVs. Screening in genetically 
diverse mouse populations may yield mouse models with 
a range of clinically relevant phenotypes that more closely 
reflect the plethora of respiratory disease outcomes observed 
in the human population. Experiences from SARS-CoV and 
MERS-CoV have taught researchers that each hCoV may 
require unique approaches for mouse model development. 
The mouse tools instituted for SARS-CoV and MERS-CoV 
constitute a versatile preclinical platform for addressing 
global pathogen preparedness, a directive of the World 
Health Organization.
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